Conditions: Postmenopausal Osteoporosis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 833
Healthy volunteers: no

Brief summary:
This is a multi-center, randomized, open-label, parallel group, study being conducted in the United States and in Europe in postmenopausal women. Approximately 800 subjects will be randomized across about 65 sites in a 1:1 ratio to either denosumab 60mg SC Q6M, or ibandronate 150mg PO QM.

Detailed description:

Arms:
arm 1: Ibandronate 150mg PO QM (tablet) arm 2: denosumab 60mg Subcutaneous Q6M (pre-filled syringe)

Interventions: intervention 1: Ibandronate intervention 2: Denosumab
Intervention descriptions: intervention 1: Ibandronate 150mg PO QM (tablet) intervention 2: denosumab 60mg SC Q6M (pre-filled syringe)

Protocol document: